These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2091873)

  • 1. Stabilized human insulin prevents catheter occlusion during continuous subcutaneous insulin infusion.
    Walter HM; Timmler R; Mehnert H
    Diabetes Res; 1990 Feb; 13(2):75-7. PubMed ID: 2091873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes.
    Hoogma RP; Schumicki D
    Horm Metab Res; 2006 Jun; 38(6):429-33. PubMed ID: 16823727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose profiles in a type 1 diabetic patient successively treated with CSII using regular insulin, lispro and an implantable insulin pump.
    Catargi B; Breilh D; Roger P; Tabarin A
    Diabetes Metab; 2000 May; 26(3):210-4. PubMed ID: 10880895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Present role of continuous subcutaneous insulin infusion (CSII) by insulin pump in the treatment of diabetes mellitus].
    Pfützner A; Berger S; Spinas G
    Schweiz Med Wochenschr; 2000 Dec; 130(48):1854-61. PubMed ID: 11132530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free insulin profiles during intensive treatment with biosynthetic human insulin.
    Olsson PO; Arnqvist HJ; Von Schenck HV
    Diabete Metab; 1988; 14(3):253-8. PubMed ID: 3044863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone.
    Thomas RM; Aldibbiat A; Griffin W; Cox MA; Leech NJ; Shaw JA
    Diabet Med; 2007 Jul; 24(7):778-83. PubMed ID: 17535290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin delivery by implantable pumps.
    Zoltobrocki M
    Horm Metab Res Suppl; 1992; 26():140-5. PubMed ID: 1490683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Needle detachment from the Sure-T infusion set in two young children with diabetes mellitus (DM) treated with continuous subcutaneous insulin infusion (CSII) and unexplained hyperglycaemia.
    Massa G; Gys I; Eyndt AO; Wauben K; Vanoppen A
    J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):237-9. PubMed ID: 25153227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant time until catheter occlusion alerts in currently marketed insulin pumps at two basal rates.
    van Bon AC; Dragt D; DeVries JH
    Diabetes Technol Ther; 2012 May; 14(5):447-8. PubMed ID: 22548715
    [No Abstract]   [Full Text] [Related]  

  • 14. A preliminary trial of the programmable implantable medication system for insulin delivery.
    Saudek CD; Selam JL; Pitt HA; Waxman K; Rubio M; Jeandidier N; Turner D; Fischell RE; Charles MA
    N Engl J Med; 1989 Aug; 321(9):574-9. PubMed ID: 2761602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study.
    Renard E; Guerci B; Leguerrier AM; Boizel R;
    Diabetes Technol Ther; 2010 Oct; 12(10):769-73. PubMed ID: 20809682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors, and obstructing materials.
    Renard E; Baldet P; Picot MC; Jacques-Apostol D; Lauton D; Costalat G; Bringer J; Jaffiol C
    Diabetes Care; 1995 Mar; 18(3):300-6. PubMed ID: 7555471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of abdominal location of the catheter on the efficacy of intraperitoneal insulin infusion using implantable and programmable pumps in type I diabetes.
    Pinget M; Jeandidier N; Keipes M; Louy S; Vetter A
    Transplant Proc; 1992 Jun; 24(3):945-6. PubMed ID: 1604676
    [No Abstract]   [Full Text] [Related]  

  • 18. Unexplained hyperglycemia in continuous subcutaneous insulin infusion: evaluation and treatment.
    Ponder SW; Skyler JS; Kruger DF; Matheson D; Brown BW
    Diabetes Educ; 2008; 34(2):327-33. PubMed ID: 18375782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of circulating insulin antibodies in two patients treated with continuous subcutaneous infusion of human insulin (recombinant DNA).
    Spijker AJ; Poortman J; Thijssen JH; Erkelens DW
    Diabetes Care; 1982; 5 Suppl 2():171-4. PubMed ID: 6765531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic procedures for catheter malfunction in programmable implantable intraperitoneal insulin infusion devices.
    Olsen CL; Turner DS; Iravani M; Waxman K; Selam JL; Charles MA
    Diabetes Care; 1995 Jan; 18(1):70-6. PubMed ID: 7698051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.